Ron H J Mathijssen et al.
Journal of the National Cancer Institute, 96(21), 1585-1592 (2004-11-04)
Irinotecan is a topoisomerase I inhibitor that has been approved for use as a first- and second-line treatment for colorectal cancer. The response to irinotecan is variable, possibly because of interindividual variation in the expression of the enzymes that metabolize